Amarin Corp Plc (AMRN)

[biolover]

Furthermore, there was a statistically significant decrease in median non-HDL-C (total cholesterol less "good cholesterol") compared to placebo with both of the AMR101 treated groups (-18% for the 4 gram group [p < 0.001] and -8% for the 2 gram group [p < 0.05]).

There were also statistically significant reductions in several important lipid markers, including Apo B, Lp-PLA2 (Lipoprotein-phospholipase A2), VLDL-C and Total Cholesterol. These results are particularly encouraging given that no other TG-lowering therapy studies have shown such results. For these achieved endpoints, p-values were <0.01 for most and <0.05 for all. Apo B (Apolipoprotein B) is a sensitive index of residual cardiovascular risk and is generally considered to be a better predictor than LDL-C. Lp-PLA2 is an enzyme found in blood and atherosclerotic plaque; high levels have been implicated in the development and progression of atherosclerosis.

Old these are the date from marine. your points are very valid. but EPA is reducing APO B and VLDL C and NOn HDL C all stastically significant , what else can any tryglyceride drug can offer. I understand loveza is not going awaay,, but i and my co won,t prescribe loveza to any body if AMR 101 is in market, becuase it is simply much much much better drug..

As a doctor it does not make sense for me to prescribe loveza if AMR 101 is in market.